Looking for a new panacea in ALK-rearranged NSCLC: May be Ceritinib?

Expert Opinion on Therapeutic Targets

Volumn 18, Issue 9, 2014, Pages 983-985

  Rolfo, Christian ^a   Passiglia, Francesco ^a   Russo, Antonio ^b   Pauwels, Patrick ^a  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^b UNIVERSITY OF PALERMO   (Italy)

Author keywords

Ceritinib; Crizotinib; EML4 ALK; NSCLC

Indexed keywords

BIOLOGICAL MARKER; CERITINIB; CRIZOTINIB; ANAPLASTIC LYMPHOMA KINASE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; SULFONE;

ALGORITHM; ALK GENE; CANCER PATIENT; CANCER RESEARCH; CANCER RESISTANCE; GENE REARRANGEMENT; HUMAN; LUNG NON SMALL CELL CANCER; ONCOGENE; PERSONALIZED MEDICINE; REVIEW; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG APPROVAL; DRUG DESIGN; GENETICS; LUNG NEOPLASMS; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PROCEDURES;

CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS, PHASE I AS TOPIC; DRUG APPROVAL; DRUG DESIGN; GENE REARRANGEMENT; HUMANS; INDIVIDUALIZED MEDICINE; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIDINES; PYRIMIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; SULFONES;

EID: 84906229861     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2014.936383     Document Type: Review

References (10)

1. Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009;27:4247-53
2. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448:561-6
3. Camidge DR, Bang YJ, Kwak EL, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 2012;13:1011-19
4. Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013;368:2385-94
5. Mok T, Kim DW, Wu YL, et al. First-line crizotinib versus pemetrexed-cisplatin or pemetrexed- carboplatin in patients (pts) with advancedALK-positive non-squamous non-small cell lung cancer (NSCLC): results of a phase III study (PROFILE 1014). J Clin Oncol 2014;32:5s
6. Katayama R, Shaw AT, Khan TM, et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. Sci Transl Med 2012;4:120ra117
7. Doebele RC, Pilling AB, Aisner DL, et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res 2012;18:1472-82
8. Rolfo C, Passiglia F, Castiglia M, et al. ALK and crizotinib: after the honeymoon... what else? Resistance mechanisms and new therapies to overcome it. Transl Lung Cancer Res 2014. doi: 10. 3978/j. issn. 2218-6751. 2014. 03. 01
9. Shaw AT, Kim DW, Mehra R, et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med 2014;370:1189-97
10. Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov 2014;4:662-73